Welcome to our dedicated page for Naturl Alt Intl news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Naturl Alt Intl stock.
The Natural Alternatives International, Inc. (NAII) news page on Stock Titan aggregates company announcements, earnings releases, and regulatory updates for investors following this nutritional supplements manufacturer. NAI describes itself as a formulator, manufacturer, and marketer of customized nutritional supplements, with operations that include private-label contract manufacturing and patent and trademark licensing related to proprietary ingredients such as CarnoSyn® beta-alanine and TriBsyn™.
News items commonly include quarterly and annual financial results, where NAI reports net sales, segment performance for private-label contract manufacturing and CarnoSyn® beta-alanine royalty, licensing and raw material sales, and commentary on factors affecting profitability such as factory capacity utilization, sales mix, and operating costs. These releases also provide information on cash balances, working capital, and borrowing capacity under the company’s credit facility.
Investors can also find corporate and commercial updates, such as new or amended manufacturing agreements and distribution partnerships. For example, NAI has announced a multi-year Manufacturing Agreement with The Juice Plus+ Company covering capsule and powder products sold in over 24 markets, and a U.S. distribution agreement for TriBsyn™ with B&D Nutritional Ingredients. Such news highlights NAI’s customer relationships and the commercial rollout of its proprietary ingredients.
Another category of news covers product and scientific developments. NAI and CarnoSyn® Brands have issued press releases about clinical research on TriBsyn™, including a published study demonstrating increased beta-alanine bioavailability and elimination of paresthesia, as well as participation in scientific conferences like the ESPEN Congress on Clinical Nutrition & Metabolism.
By reviewing this news feed, readers can track NAII earnings announcements, material agreements, scientific milestones, and other company communications in one place.
Natural Alternatives International (NAII) reported a net income of $1.9 million ($0.30 per diluted share) for Q3 FY2021, reversing a net loss of $4.0 million in Q3 FY2020. Net sales surged 81.8% to $46.3 million, boosted by a significant increase in private-label contract manufacturing sales, which grew 86.2%. For the nine months ending March 31, 2021, net income was $7.8 million compared to a loss of $3.4 million in the previous year. The company expects annualized FY2021 net sales to rise by 45% to 55%, while also maintaining strong cash reserves of $28.1 million.
Natural Alternatives International, Inc. (NAII) has announced a $3.0 million increase to its stock repurchase plan, raising the total authorization to $15.0 million. This plan allows for the repurchase of shares based on market conditions, with 1.6 million shares already acquired. After this increase, $3.2 million remains available for further repurchases. The company's stock buyback strategy aims to enhance shareholder value amid ongoing market dynamics.
Natural Alternatives International, Inc. (NAII) has released an investor presentation aimed at enhancing communication with current and potential shareholders. The presentation is part of a broader initiative to articulate the company's long-term direction and management goals. CEO Mark A. Le Doux highlighted the firm’s plans to engage more with institutional investors and participate in conferences, signaling optimism about upcoming opportunities in their pipeline. The presentation is accessible on their investor relations webpage.
Natural Alternatives International (NAII) reported a significant increase in net income to $3.6 million ($0.57/share) for Q2 FY2021, a notable rise from $0.5 million ($0.07/share) last year. Net sales reached $48.1 million, up 65.2% from $29.1 million. Private-label contract manufacturing soared by 82.5%, whereas CarnoSyn® sales dropped 35.5%, impacted by competition and COVID-19. Year-to-date income stands at $5.9 million ($0.91/share), with expectations of 30% to 50% sales growth for FY2021 and operating income between 5% and 7%. Cash as of December 31, 2020, was $28.6 million.
Natural Alternatives International, Inc. (NAII) announced the full repayment of its outstanding $10 million credit line with Wells Fargo Bank as of February 2, 2021. This credit line was initially secured during the early pandemic uncertainty in March 2020. CEO Mark A. Le Doux emphasized that the strong business environment and increased consumer demand for dietary supplements made this repayment feasible. The line of credit is now available again for future needs through November 2022, reflecting the company’s solid cash flow and financial health.
Natural Alternatives International, Inc. (NAII) reported a net income of $2.3 million, or $0.35 per diluted share, with net sales reaching $39.7 million for the first quarter of fiscal 2021, ending September 30, 2020. This reflects a 36.1% increase in sales compared to the previous year. The company attributed growth to increased private-label contract manufacturing, particularly in immune and wellness products amid the COVID-19 pandemic. However, royalty and licensing revenue from CarnoSyn® beta-alanine declined 15.9%. NAII expects annual sales to rise 30% to 50% in fiscal 2021.
Natural Alternatives International, Inc. (NAII) reported a 16% increase in consolidated net sales for Q4 2020, reaching $35.1 million. However, FY 2020 sales declined 14% to $118.9 million. The company posted a Q4 net income of $1.8 million compared to a loss of $0.02 million in Q4 2019. Net loss for FY 2020 was $1.6 million due to a $4.3 million reserve related to a former customer. A stock repurchase plan was increased by $2 million, totaling $12 million. The outlook for FY 2021 is positive, with expected sales growth.
Natural Alternatives International, Inc. (NAII) has appointed Dr. Nancy Steely as Vice President of Research and Development. Dr. Steely, a seasoned executive with over 20 years of experience in the nutraceutical industry, aims to enhance NAII's research capabilities and develop innovative products. President Ken Wolf highlighted her ability to integrate scientific research with business strategy, fostering a culture of innovation. Dr. Steely previously worked at Olly PBC and other notable companies, and she expresses enthusiasm for collaborating with clients to create compliant, science-based products.
Natural Alternatives International, Inc. (NAII) has announced that Jeff DaVanon has joined CarnoSyn® Brands as the Health & Wellness Business Development Manager. With over ten years of experience in the nutraceutical industry, DaVanon will enhance sales and customer relations for SR CarnoSyn®, focusing on wellness and healthy aging. His unique background as a former major league baseball player complements his extensive knowledge in nutraceuticals. This leadership change aims to capitalize on the growing wellness market, as CarnoSyn® Brands continues to expand its innovative product offerings.